Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

408
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
408
T Cell Types and Functions01:24

T Cell Types and Functions

2.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

11.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.6K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

375
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
375
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

423
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
423
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health economic evaluations of myasthenia gravis: a systematic review.

Croatian medical journal·2026
Same author

Ultrasound-based population survey for abdominal cystic echinococcosis in Albania: Results from the NDTND project.

PLoS neglected tropical diseases·2025
Same author

Natural Compounds Targeting <i>SIRT1</i> and Beyond: Promising Nutraceutical Strategies Against Atherosclerosis.

Nutrients·2025
Same author

An Overview of the Role of Medicinal Plants in Parkinson's Disease: A Semi-Systematic Review.

Biomedicines·2025
Same author

Mycotoxins and neuropsychiatric symptoms: possible role in special refugee populations.

Frontiers in pharmacology·2025
Same author

Estimating the Prevalence of Cognitive Impairment and Its Associated Factors in Albania: A Nationwide Cross-Sectional Study.

Brain sciences·2024

Related Experiment Video

Updated: Jan 1, 2026

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K

CYP-derived eicosanoids: Implications for rheumatoid arthritis.

Malvina Hoxha1, Bruno Zappacosta1

  • 1Catholic University Our Lady of Good Counsel, Department of Chemical-Toxicological and Pharmacological Evaluation of Drugs, Rruga Dritan Hoxha, Tirana, Albania.

Prostaglandins & Other Lipid Mediators
|December 16, 2019
PubMed
Summary

Cytochrome P450 metabolites play a key role in rheumatoid arthritis (RA). Epoxyeicosatrienoic acids (EETs) show anti-inflammatory effects, while 20-hydroxyeicosatetraenoic acid (20-HETE) is pro-inflammatory, offering therapeutic targets for RA.

Keywords:
Cytochrome P450EETHETEInflammationRheumatic disease

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

915
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

750

Related Experiment Videos

Last Updated: Jan 1, 2026

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

915
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

750

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • The role of cytochrome P450 (CYP) metabolites in rheumatoid arthritis (RA) is not well understood.
  • CYP epoxygenase and ω-hydroxylase pathways influence NF-κB regulation, a key inflammatory pathway.

Purpose of the Study:

  • To review current knowledge on CYP metabolites in RA.
  • To explore potential therapeutic strategies targeting CYP-mediated eicosanoid metabolism in RA.

Main Methods:

  • Literature review of studies on CYP enzymes, their metabolites, and RA.
  • Analysis of the interplay between inflammatory markers (e.g., IL-6) and CYP activity in RA patients.

Main Results:

  • Elevated IL-6 in RA synovial fluid suppresses CYP enzyme activity.
  • Epoxyeicosatrienoic acids (EETs) exhibit anti-inflammatory properties and inhibit bone resorption, suggesting therapeutic potential.
  • 20-hydroxyeicosatetraenoic acid (20-HETE) acts as a pro-inflammatory mediator in RA.

Conclusions:

  • Soluble epoxide hydrolase (sEH) inhibitors, which increase EET levels, represent a promising therapeutic strategy for RA.
  • Combination therapies, including sEH inhibitors with other anti-inflammatory agents, warrant further investigation.
  • Further research is needed to elucidate the complex role of CYP-derived eicosanoids in inflammatory rheumatic diseases.